Firm at a glance
Longitude Capital is a platform private equity firm founded in 2006 with offices in Menlo Park, California and Boston, Massachusetts, per its own website [S1].
What they buy
Longitude Capital’s portfolio demonstrates a concentrated focus on life sciences investments, spanning both biotechnology and medical technology companies [S1]. The firm’s publicly disclosed holdings include approximately 21 companies across these two sectors, with a roughly even split between therapeutic development businesses and medical device innovators [S1]. The firm has reportedly raised over $2 billion across six funds since its founding [S1].
Portfolio
Medical Technology
The firm’s medical technology portfolio includes Bolt Medical, Ceribell, Endogenex, Nalu Medical, RxSight, Sydnexis, Kestra Medical, and Polares Medical [S1].
Biotechnology
Biotechnology holdings include BioAge Labs, CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals, Opna Bio, Orbus Therapeutics, Vera Therapeutics, Veradermics, Zenas BioPharma, Alentis Therapeutics, CG Oncology, and Helicore Biopharma [S1].
Recent activity (last 24 months)
* July 2024: Participated in a $196 million financing round for Kestra Medical Technologies [S2]
* November 12, 2024: Participated in an oversubscribed $181.4 million Series D financing for Alentis Therapeutics to advance clinical development of anti-claudin-1 ADCs in solid tumors [S3]
How this firm fits a seller
Longitude Capital appears positioned for founder-led life sciences companies seeking capital partners with sector depth in biotechnology and medical devices. The firm’s recent activity suggests continued appetite for both early-stage therapeutic platforms and medical technology businesses requiring growth capital. For sellers in the healthcare innovation space, particularly those developing novel medical devices or therapeutic modalities, the firm’s two-decade track record and dual-coast presence may offer relevant sector expertise. The firm’s participation in large financing rounds during 2024 indicates active deployment capacity.
Sources
[S1] https://longitudecapital.com (as of 2025-01-10)
[S2] https://www.lw.com/en/news/2024/07/latham-watkins-advises-on-kestra-medical-technologies-us196-million-financing-round (as of 2024-07)
[S3] https://www.businesswire.com/news/home/20241112618033/en/Alentis-Therapeutics-Raises-%24181.4-Million-in-an-Oversubscribed-Series-D-Financing-to-Advance-the-Clinical-Development-of-Anti-Claudin-1-ADCs-in-Solid-Tumors (as of 2024-11-12)
Frequently asked questions
Does Longitude Capital buy medical technology businesses?
Yes, approximately half of Longitude Capital’s publicly disclosed portfolio consists of medical technology companies [S1]. The firm’s medical device holdings include businesses such as Ceribell, RxSight, Nalu Medical, and Kestra Medical, among others [S1]. The firm participated in a $196 million financing for Kestra Medical Technologies as recently as July 2024 [S2].
What companies has Longitude Capital acquired recently?
Recent publicly disclosed transactions include participation in a $196 million financing round for Kestra Medical Technologies in July 2024 [S2] and involvement in Alentis Therapeutics’ $181.4 million Series D round in November 2024 [S3]. The firm’s portfolio also includes companies such as Ceribell, Vera Therapeutics, and CG Oncology [S1].
Where is Longitude Capital based and how big is the firm?
Longitude Capital maintains offices in Menlo Park, California and Boston, Massachusetts [S1]. The firm has reportedly raised over $2 billion across six funds since its 2006 founding [S1]. The firm’s portfolio includes approximately 21 publicly disclosed companies across biotechnology and medical technology sectors [S1].
Is Longitude Capital still actively acquiring?
Yes, Longitude Capital demonstrated active investment activity in 2024, participating in two significant financing rounds: a $196 million round for Kestra Medical Technologies in July 2024 [S2] and a $181.4 million Series D for Alentis Therapeutics in November 2024 [S3].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.